ReAlta Life Sciences Raises $40M to Advance Precision Therapies for Inflammatory Disease
ReAlta Life Sciences just pulled in $40M in an oversubscribed financing, pushing total capital raised to $150M+ since 2018, and if you read between the lines, this wasn’t capital chasing noise, this was capital underwriting conviction. No lead investor named, no vanity parade, just demand that outpaced supply. That usually means the people writing checks did the homework and decided to move before the data makes the decision more expensive.
ReAlta Life Sciences is not building another single-thread biotech story. The foundation comes out of work by Neel K. Krishna, Ph.D. and Kenji Cunnion, M.D., MPH, rooted in a human astrovirus mechanism that figured out how to quiet inflammation without breaking the system it protects. That insight turned into the EPICC peptide platform, now scaled across 160+ engineered peptides designed to rebalance, not suppress, the immune response. Their lead asset, pegtarazimod, is a 15-amino-acid peptide doing double duty, targeting complement activation at C1 while also shutting down neutrophil-driven damage like MPO activity and NET formation. That dual mechanism matters when the alternative is choosing which part of inflammation to ignore.
The company is advancing 3 active Phase 2 programs, and each one is a different angle on the same problem. The STAR trial in neonatal HIE is running across 13 NICUs in the United States, going after a condition affecting roughly 1.2M babies globally each year with no approved drug therapy. In parallel, the AURORA trial is tackling steroid-refractory acute GvHD with both FDA Orphan Drug and Fast Track designations already in hand, while a separate Phase 2 study in AE-COPD has been enrolling since the first patient was dosed in February 2024. This is one molecule, multiple shots on goal, all tied to the same underlying biology.
Leadership is not an afterthought here. Howard Berman, Ph.D., CEO stepped in during March 2026, bringing experience from Coya Therapeutics and prior roles across AbbVie, Eli Lilly, and Novartis, which signals a company thinking beyond clinical milestones toward market reality. Alongside him, Kia Motesharei, Ph.D., President and COO arrives with 100+ transactions across licensing, M&A, and financings, including work tied to raising over $1B and supporting an FDA-approved therapy. John Rickman, CFO anchors the financial discipline, making sure the science doesn’t outrun the balance sheet.
The $40M is being deployed with precision, complete the STAR trial, deliver top-line data, and walk into an End-of-Phase 2 FDA meeting with leverage. No detours, no science projects, just a straight line from data to decision. With additional programs in motion and a platform designed to stretch across 25+ inflammatory indications, the real story is not just what ReAlta Life Sciences is building, but how many places this mechanism can land once it proves itself.
Capital didn’t just show up here, it aligned around a platform that treats inflammation like a system to rebalance instead of a target to eliminate. That distinction is where most companies lose the plot. ReAlta Life Sciences is betting that precision beats force, and now they have the funding to prove it.
